Sequential versus concurrent chemo-radiotherapy in inoperable stage III non-small cell lung cancer

Anticancer Research

Volumn 26, Issue 1 B, 2006, Pages 495-505

  El Sharouni, S Y ^a   Kal, H B ^a   Battermann, J J ^a   Schramel, F M N H ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Concurrent chemo radiotherapy; Inoperable non small cell lung cancer; Review; Sequential chemo radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; UFT; VINBLASTINE; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INOPERABLE CANCER; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; META ANALYSIS; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; OVERALL SURVIVAL; PATIENT CARE PLANNING; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT PLANNING;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG NEOPLASMS; META-ANALYSIS; NEOPLASM STAGING; SURVIVAL RATE;

EID: 32144451021     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Weir HK, Thun MJ, Hankey BF et al: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95: 1276-1299, 2003.
2. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997.
3. Perez CA, Pajak TF, Rubin P et al: Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 59: 1874-1881, 1987.
4. Johnson DH, Einhorn LH, Bartolucci A et al: Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 113: 33-38, 1990.
5. Sibley GS, Jamieson TA, Marks LB et al: Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 40: 149-154, 1998.
6. Graham PH, Gebski VJ and Langlands AO: Radical radiotherapy for early nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 31: 261-266, 1995.
7. Cox J, Azaria, N, Byhardt, R et al: A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 to 79.2 Gy: possible survival benefits with > 69.6 Gy in favorable patients with stage III Radiation Therapy Oncology Group 83-11. J Clin Oncol 8: 1543-1555, 1990.
8. Saunders M, Dische S, Barrett A et al: Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 350: 161-165, 1997.
9. Saunders MI, Rojas A, Lyn BE et al: Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer. Br J Cancer 78: 1323-1328, 1998.
10. Koutaissoff S, Wellmann D, Coucke P et al: Hyperfractionated accelerated radiotherapy (HART) for inoperable, nonmetastatic non-small cell lung carcinoma of the lung (NSCLC): results of a phase II study for patients ineligible for combination radiochemotherapy. Int J Radiat Oncol Biol Phys 45: 1151-1156, 1999.
11. Mehta M, Tannehill, S, Adak, S et al: Phase II trial of hyperfractionated accelerated radiation therapy for non-resectable non-small-cell lung cancer: Results of Eastern Cooperative Oncology Group 4593. J Clin Oncol 16: 518-523, 1998.
12. Cox JD, Pajak TF, Asbell S et al: Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 27: 493-498, 1993.
13. Rapp E, Pater JL, Willan A et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 6: 633-641, 1988.
14. Jett JR, Scott WJ, Rivera MP et al: American College of Chest Physicians. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 123(1 Suppl): 221S-225S, 2003.
15. Sirzén F, Kjellén E, Sörenson S et al: A systematic overview of radiation therapy effects in non-small cell lung cancer. Acta Oncol 42: 493-515, 2003.
16. Marino P, Preatoni A and Cantoni A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 76: 593-601, 1995.
17. Pritchard RS and Anthony SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer: a meta-analysis. Ann Intern Med 125: 723-729, 1996.
18. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995.
19. Sorenson S, Glimelius B and Nygren P: SBU-group. Swedish Council of Technology Assessment in Health Care: a systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol 40: 327-339, 2001.
20. Robinson LA, Wagner H Jr and Ruckdeschel JC: American College of Chest Physicians: Treatment of stage IIIA non-small cell lung cancer. Chest 123(1 Suppl): 202S-220S, 2003.
21. Sause W, Kolesar P, Taylor S IV et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117: 358-364, 2000.
22. Kim TY, Yang SH, Lee SH et al: A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol 25: 238-243, 2002.
23. Mehta MP, Wang W, Johnson D et al: Induction chemotherapy followed by standard thoracic radiotherapy vs. hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small cell lung cancer: phase III study of the Eastern Cooperative Oncology Group (ECOG 2597). Abstract. Int J Radiat Oncol Biol Phys 57: S141, 2003.
24. Vokes EE, Herndon JE II, Crawford J et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20: 4191-4198, 2002
25. Willner J, Huber H, Poellinger B et al: CTRT 99/97 a randomized trial of simultaneous paclitaxel and radiotherapy vs. radiotherapy alone following induction chemotherapy in stage III inoperable NSCLC. Abstract. Int J Radiat Oncol Biol Phys 57: S140, 2003.
26. Brodin O, Nou E, Mercke C et al: Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. The Swedish Lung Cancer Study Group. Eur J Cancer 32A: 1893-1900, 1996.
27. Crino L, Latini P, Meacci M et al: Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol 4: 847-851, 1993.
28. Cullen MH, Billingham LJ, Woodroffe CM et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17: 3188-3194, 1999.
29. Dillman RO, Herndon J, Seagren SL et al: Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88: 1210-1215, 1996.
30. Gregor A, Macbeth FR, Paul J et al: Radical radiotherapy and chemotherapy in localized inoperable non-small-cell lung cancer: a randomized trial. J Natl Cancer Inst 85: 997-999, 1993.
31. Le Chevalier T, Arriagada R, Tarayre M et al: Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 84: 58, 1992.
32. Kubota K, Furuse K, Kawahara M et al: Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol 12: 1547-1552, 1994.
33. Sculier JP, Paesmans M, Lafitte JJ et al: A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party. Ann Oncol 10: 295-303, 1999.
34. Wolf M, Hans K, Becker H et al: Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer. Semin Oncol 21(3 Suppl 4): 42-47, 1994
35. Furuse K, Fukuoka M, Kawahara M et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692-2699, 1999.
36. Curran WJ, Scott CB, Langer CJ et al: Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Am Soc Clin Oncol, abstract 2499, 2003.
37. Pierre F, Maurice P, Gilles R et al: A randomized phase III trial of sequential chemoradiotherapy in locally advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 20: 312a, 2001.
38. Zatloukal P, Petruzelka L, Zemanova M et al: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 246: 87-98, 2004.
39. Choi JH, Lim HY, Kim HC et al: The addition of induction chemotherapy failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer. Abstract. Lung Cancer 41 (Suppl 2): S238, 2003.
40. Graham PH, Abell FL, Capp A et al: Concurrent end-phase boost radiation therapy to 65 Gy in 5 weeks for non-small cell lung cancer with or without cisplatin chemotherapy. Abstract. Lung Cancer 41(Suppl 2): S243-245, 2003.
41. Saha S, Das Gupta P and Gangopadhaya S: Various chemoradiation modalities in inoperable non-small-cell lung cancer: an Indian experience. Abstract. Lung Cancer 45: S54-55, 2004.
42. Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J and Green MR: Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17: 4-11, 1999.
43. Jeremic B, Shibamoto Y, Acimovic L et al: Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/ etoposide with or without weekend carboplatin/ etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 50: 19-25, 2001.
44. Ichinose Y, Nakai Y, Kudoh S et al: Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a multi-institutional phase II trial: Clin Cancer Res 10: 4369-4373, 2004.
45. Ball D, Bishop J, Smith J et al: A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 52: 129-136, 1999.
46. Blackstock AW, Case LD, Ho C et al: Gemcitabine and concurrent thoracic radiotherapy. A phase I/II study in patients with advanced non-small cell lung cancer. Abstract. Lung Cancer 41(Suppl 2): S243, 2003.
47. Dediu M, Tarlea A, Iorga P et al: Split course radiation with concurrent vinorelbine (NVB) and cisplatin (CDDP) in locally advanced non-small cell lung cancer (NSCLC). A phase II study. Abstract. Lung Cancer 41(Suppl 2): S238, 2003.
48. Kim DW, Shyr Y, Akerley WL et al: Tumor responsiveness to combined modality therapy is highly significant predictor of survival for patients with locally advanced non-small cell lung cancer. Abstract. Lung Cancer 41(Suppl 2): S239-240, 2003.
49. Maguire J, Page R, Kelly V et al: Improved local control and survival in stage III NSCLC with concurrent cisplatinum and radical radiotherapy in four weeks. Abstract. Lung Cancer 41(Suppl 2): S245, 2003.
50. Park J, Ahn YC, Kim H et al: A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers. Lung Cancer 42: 227-235, 2003.
51. Ryu MH, Kim SW, Hwang CY et al: Severe radiation pneumonitis after concurrent chemoradiation therapy in locally advanced non-small cell lung cancer: risk factors and the prognosis. Abstract. Lung Cancer 41(Suppl 2): S238-239, 2003.
52. Rusu P, Ciuleanu TE, Cernea D et al: Concurrent chemoradiotherapy with navelbine and cisplatin for unresectable stage III NSCLC: a phase II study. Abstract. Lung Cancer 41(Suppl 2): S241, 2003.
53. Takayama K, Nakanishi Y, Kawasaki M et al: Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer. Abstract. Lung Cancer 41(Suppl 2): S243, 2003.
54. Kaplanova J, Spelda S, Skrickova J et al: Concomitant chemotherapy with paclitaxel, carboplatin and radiotherapy in the treatment of locoregionally advanced non-small-cell lung cancer. Abstract. Lung Cancer 45: S59, 2004.
55. Zajusz A, Nowicka E, Behrendt K et al: The efficacy of concurrent thoracic radiotherapy and gemcitabine in locally advanced NSCLC patients (LA-NSCLC) - long-term results. Abstract. Lung Cancer 45: S59-60, 2004.
56. El Sharouni SY, Kal HB and Battermann JJ: Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer 89: 2184-2189, 2003
57. Koukourakis M, Hlouverakis G, Kosma L et al: The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 34: 315-322, 1996.
58. Fowler JF and Chappell R: Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys 46: 516-517, 2000.
59. Webb S and Nahum AE: A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. Phys Med Biol 38: 653-666, 1993.
60. Webb S: Optimum parameters in a model for tumour control probability including interpatient heterogeneity. Phys Med Biol 39: 1895-1914, 1994.
61. Werner-Wasik M, Scott C, Movas B et al: Amifostine as mucosal protectant in patients with locally advanced non-small cell lung cancer (NSCLC) receiving intense chemotherapy and thoracic radiotherapy (RT): results of the Radiation Therapy Oncology Group (RTOG) 98-01 study. Abstract. Int J Radiat Oncol Biol Phys 57(Suppl 2): S216, 2003.
62. Xian CJ: Roles of growth factors in chemotherapy-induced intestinal mucosal damage repair. Curr Pharm Biotechnol 4: 260-269, 2003.
63. Senan S, De Ruysscher D, Girraud P et al: Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71: 139-146, 2004.
64. Socinski MA, Zhang C, Herndon JE II et al: Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 15: 1033-1041, 2004.
65. Sakai H, Yoneda S, Kobayashi K et al: Phase II study of biweekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. Lung Cancer 43: 195-201, 2004.
66. Gandara DR, Chansky K, Albain KS et al: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21: 2004-2010, 2003.
67. Gaafar RM, Abdelbaki H, Safwat A et al: Accelerated hyperfractionation radiotherapy and daily cisplatin followed by consolidation chemotherapy. A phase II trial for patients with inoperable stage III NSCLC. Abstract. Lung Cancer 45: S53-54, 2004.
68. Ramsay J, Suit HD and Sedlacek R: Experimental studies on the incidence of metastases after failure of radiation treatment and the effect of salvage surgery. Int J Radiat Oncol Biol Phys 14: 1165-1168, 1988.
69. Fu XL, Jiang GL, Wang LJ et al: The value of local control in the radiation therapy for non-small cell lung cancer. Shanghai Med 19: 559-561, 1996.
70. Freiha FS and Bagshaw MA: Carcinoma of the prostate: results of post-irradiation biopsy. Prostate 5: 19-25, 1984.
71. Whelan TJ, Julian J, Wright J et al: Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 18: 1220-1229, 2000.